Human heart generates complement proteins that are upregulated and activated after myocardial infarction

Circulation Research

Volumn 83, Issue 8, 1998, Pages 860-869

  Yasojima, Koji ^a   Schwab, Claudia ^a   McGeer, Edith G ^a   McGeer, Patrick L ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Classical pathway; Complement gene expression; Immunohistochemistry; Liver complement; Postmortem delay; Western blotting

Indexed keywords

CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1R; COMPLEMENT COMPONENT C1S; COMPLEMENT COMPONENT C2; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C6; COMPLEMENT COMPONENT C7; COMPLEMENT COMPONENT C8; COMPLEMENT COMPONENT C9;

ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT SYSTEM; ENZYME INHIBITION; HEART INFARCTION; HEART MUSCLE CELL; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REPERFUSION INJURY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE INJURY;

EID: 0032547767     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.83.8.860     Document Type: Article

References (46)

1. Hugo F, Handoch T, Mathey D, Schofer HJ, Bhakdi S. Quantitative measurement of SC5b-9 and C5b-9(m) in infarcted areas of human myocardium. Clin Exp Immunol. 1990;81:132-136.
2. Langlois PF, Gawryl MS. Detection of the terminal complement complex in patient plasma following acute myocardial infarction. Atherosclerosis. 1988;70:95-105.
3. Schafer H, Mathey D, Hugo F, Bhakdi S. Deposition of the terminal C5b-9 complex in infarcted areas of human myocardium. J Immunol. 1986;137:1945-1949.
4. Tada T, Okada H, Okada N, Tateyama H, Suzuki H, Takahashi Y, Eimoto T. Membrane attack complex of complement and 20 kDa homologous restriction factor (CD59) in myocardial infarction. Virchows Arch. 1997; 430:327-332.
5. Lagrand WK, Niessen HWM, Wolbink GJ, Jaspars LH, Visser CA, Verheugt FWA, Meijer CJL, Hack CE. C-Reactive protein colocalized with complement in human hearts during acute myocardial infarction. Circulation. 1997;97:97-103.
6. Schafer H, Mathey D, Bhakdi S. C5b-9 deposition as an immunocytochemical marker for early myocardial infarction and vascular injury. Pathol Res Pract. 1987;182:553. Abstract.
7. Vakeva A, Laurila P, Meri S. Regulation of complement membrane attack complex formation in myocardial infarction. Am J Pathol. 1993;143: 65-75.
8. Mathey D, Schofer J, Schafer HJ, Hamdoch T, Joachim HC, Ritgen A, Hugo F, Bhakdi S. Early accumulation of the terminal complementcomplex in the ischaemic myocardium after reperfusion. Eur Heart J. 1994;15:418-423.
9. Hill JH, Ward PA. The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med. 1971;133:885-900.
10. Beyersdorf F, Allen BS, Buckberg GD, Acar C, Okamoto F, Sjostrand F, Young HH, Bugyi HI. Studies on prolonged acute regional ischemia, I: evidence for preserved cellular viability after 6 hours of coronary occlusion. J Thorac Cardiovasc Surg. 1989;98:112-126.
11. Matsumura K, Jeremy RW, Schaper J, Becker LC. Progression of myocardial necrosis during reperfusion of ischemic myocardium. Circulation. 1998;97:795-804.
12. Pinckard RN, O'Rourke RA, Crawford MH, Grover FS, McManus LM, Ghidoni JJ, Storrs SB, Olson MS. Complement localization and mediation of ischemic injury to baboon myocardium. J Clin Invest. 1980;66:1050-1056.
13. Crawford MH, Grover FL, Kolb WP, McMahan CA, O'Rourke RA, McManus LM, Pinckard RN. Complement and neutrophil activation in the pathogenesis of ischemic myocardial injury. Circulation. 1988;78: 1449-1458.
14. Vakeva A, Morgan BP, Tikkanen I, Helin K, Laurila P, Meri S. Time course of complement activation and inhibitor expression after ischemic injury of rat myocardium. Am J Pathol. 1994;144:1357-1368.
15. Homeister JW, Lucchesi BR. Complement activation and inhibition in myocardial ischemia and reperfusion. Annu Rev Pharmacol Toxicol. 1994;34:17-40.
16. Homeister JW, Satoh P, Lucchesi BR. Effects of complement activation in the isolated heart. Role of the terminal complement components. Circ Res. 1992;71:303-319.
17. Langlois PF, Gawryl MS. Detection of the terminal complement complex in patient plasma following acute myocardial infarction. Atherosclerosis. 1988;70:95-105.
18. Murahara T, Guo JP, Delyani JA, Lefer AM. Cardioprotective effects of selective inhibition of the two complement activation pathways in myocardial ischemia and reperfusion injury. Methods Find Exp Clin Pharmacol. 1995;17:499-507.
19. Vakeva A, Laurila P, Meri S. Co-deposition of clusterin with the complement membrane attack complex in myocardial infarction. Immunology. 1993;80:177-182.
20. Buerke M, Murohara T, Lefer AM. Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation. 1995;91:393-402.
21. Horstick G, Heimann A, Gotze O, Hafner G, Berg O, Boehmer P, Becker P, Darius H, Rupprecht HJ, Loos M, Bhakdi S, Meyer J, Kempski O. Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion. Circulation. 1997;95:701-708.
22. Amsterdam EA, Stahl GL, Pan HL, Rendig SV, Fletcher MP, Longhurst JC. Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. Am J Physiol. 1995;268: H448-H457.
23. Shandelya SM, Kuppusamy P, Hershowitz A, Weisfeldt ML, Zweier JL. Soluble complement receptor type 1 inhibits the complement pathway and prevents contractile failure in the postischemic heart. Evidence that complement activation is required for neutrophil-mediated reperfusion injury. Circulation. 1993;88:2812-2826.
24. Weisman HF, Bartow T, Leppo MK, Boyle MP, Marsh HC Jr, Carson GR, Roux KH, Weisfeldt ML, Fearson DT. Recombinant soluble CR1 suppressed complement activation, inflammation, and necrosis associated with reperfusion of ischemic myocardium. Trans Assoc Am Physicians. 1990;103:64-72.
25. Ito W, Schafer HJ, Bhakdi S, Klask R, Hansen S, Schaarschmidt S, Schofer J, Hugo F, Hamdoch T, Mathey D. Influence of the terminal complement-complex on reperfusion injury, no-reflow and arrhythmias: a comparison between C6-competent and C6-deficient rabbits. Cardiovasc Res. 1996;32:294-305.
26. Yasojima K, Kilgore KS, Washington RA, Lucchesi BR, McGeer PL. Complement gene expression by rabbit heart: upregulation by ischemia and reperfusion. Circ Res. 1998;82:1224-1230.
27. Shen Y, Li R, McGeer EG, McGeer PL. Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain. Brain Res. 1997;769:391-395.
28. Terai K, Walker DG, McGeer EG, McGeer PL. Neurons express proteins of the classical complement pathway in Alzheimer brain. Brain Res. 1997;769:385-390.
29. McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev. 1995;21:195-218.
30. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
31. Haendler B, Hofer-Warbinek R, Hofer E. Complementary DNA for human T-cell cyclophilin. EMBO J. 1987;6:947-950.
32. Danielson PE, Forss-Petter S, Brow MA, Calavetta L, Douglass J, Milner RJ, Sutcliffe JG. p1B15: a cDNA clone of the rat mRNA encoding cyclophilin. DNA. 1988;7:261-267.
33. Innis MA, Gelfand DH. Optimization of PCRs. In: Innis MA, Gelfand DH, Sninsky JJ, White TJ, eds. PCR Protocols. San Diego, Calif: Academic Press; 1990:3-12.
34. Lowry OH, Rosebrough NJ, Farr AL, Randall EJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.
35. Holm S. A simple sequentially repetitive multiple test procedure. Scand J Stat. 1979;6:65-70.
36. Gomori G. A rapid one-step trichrome stain. Am J Clin Pathol. 1950;20: 661-664.
37. Frank MM. Complement and kinin. In: Stites DP, Terr AI, eds. Basic and Clinical Immunology. 7th ed. Norwalk, Conn: Appleton & Lange; 1991: 161-174.
38. Brachova L, Lue L-F, Schultz J, Rashidy TE, Rogers J. Association cortex, cerebellum and serum concentrations of C1q and factor B in Alzheimer's disease. Mol Brain Res. 1993;18:329-334.
39. Wing MG, Seilly DJ, Bridgman DJ, Harrison RA. Rapid isolation and biochemical characterization of rat C1 and C1q. Mol Immunol. 1993;30: 433-440.
40. Hong Y, Ghebrehiwet B. Effect of Pseudomonas aeruginosa elastase and alkaline protease on serum complement and isolated components C1q and C3. Clin Immunol Immunopathol. 1992;62:133-138.
41. Davis AE, Harrison RA, Lachmann PJ. Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g. J Immunol. 1984;132:1960-1966.
42. Zhou W, Campbell RD, Martin J, Sacks SH. Interferon-γ regulation of C4 gene expression in cultured human glomerular epithelial cells. Eur J Immunol. 1993;23:2477-2481.
43. Maeda S, Takamaru Y, Fukatsu J, Nagasawa S. Identification of a surface structure in the fourth component of human complement, C4, which becomes hidden upon activation by C1s. Biochem J. 1993;289:503-508.
44. Hammer CH, Wirtz GH, Renfer L, Gresham HD, Tack BF. Large scale isolation of functionally active components of the human complement system. J Biol Chem. 1981;256:3995-4006.
45. Nürnberger W, Seger R, Kobler P, Mons I, Tedesco F, Wahn V. Immunoblot analysis of the eighth component of human complement. J Immunol Methods. 1988;109:257-263.
46. Biesecker G, Podack ER, Halverson CA, Muller-Eberhard HJ. C5b-9 dimer: isolation from complement lysed cells and ultrastructural identification with complement-dependent membrane lesions. J Exp Med. 1979;149:448-458.